在一个小型遗传中心的NSCLC中KRAS G12C突变:对索托拉西布治疗反应潜力的洞察

在一个小型遗传中心的NSCLC中KRAS G12C突变:对索托拉西布治疗反应潜力的洞察

相关实验视频

Updated: Jun 8, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Metin Eser¹, Gulam Hekimoglu², Murat Hakki Yarar¹

¹Department of Medical Genetics, Umraniye Education and Research Hospital, University of Health Sciences, Istanbul, Turkey.

Scientific reports

|November 4, 2024

概括

这项研究研究了非小细胞肺癌 (NSCLC) 中的KRAS突变,在20%的患者中发现了G12C变异. 那些具有KRAS G12C突变的人对索托拉西布治疗产生了积极的反应.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
分子生物学分子生物学

背景情况:

肺癌,特别是非小细胞肺癌 (NSCLC),是一个主要的健康问题.
基因组不稳定性和突变表型是肺癌发生的早期事件.
了解特定的基因突变对于有效的治疗策略至关重要.

研究的目的:

为了研究89名患有非小细胞肺癌 (NSCLC) 的患者的突变性表型.
识别常见的基因突变,特别关注KRAS基因.
根据已识别的突变来评估针对性疗法的疗效.

主要方法:

从使用Promega ReliaPrep RNA Miniprep系统的甲固定型抛嵌入 (FFPE) 组织中分离RNA.
用阿切尔FusionPlex综合甲状腺和肺部 (CTL) 套件进行基因放大.
在Illumina NextSeq平台上进行下一代测序 (NGS),并使用Archer Analysis软件对hg19参考基因组进行数据分析.

主要成果:

在研究的NSCLC患者中,KRAS基因突变在约20%的患者中被发现.
克拉斯G12C变异是主要的突变 (50%的克拉斯突变),其次是G12V和G12D (11.2%).
具有KRAS G12C突变的患者对索托拉西布治疗表现出良好的反应.

结论:

突变分析对于NSCLC个性化治疗至关重要.
在NSCLC患者中,KRAS G12C突变是显著的发现.
索托拉西布显示了作为针对性治疗的NSCLC患者具有KRAS G12C突变的有希望的疗效.

关键词:

在KRAS G12C突变中.非小细胞肺癌的非小细胞肺癌.这就是Sotorasib.

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

相关概念视频

02:57

Targeted Cancer Therapies

7.5K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.5K

02:38

The Ras Gene

6.2K

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

6.2K

Combination Therapies and Personalized Medicine

02:50

Combination Therapies and Personalized Medicine

4.9K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...